Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
20 results
- D1.536 - Immunological basis of coexisting slowly progressive insulin-dependent diabetes mellitus (SPIDDM) and Vogt–Koyanagi–Harada disease (VKH)
- D1.537 - Immunopharmacogenomics as a Systems Medicine Framework for Precision Therapy in Allergic and Immune Mediated Diseases
- D1.538 - First Report of the SERPING1 c.52-1G>A Variant in a Chinese HAE Pedigree: Severe Abdominal Phenotype Correlated with Attack-Phase Imaging
- D1.540 - Automated generation of real-world clinical databases in Allergy: a data-driven research framework
- D1.541 - Addressing Allergy undergraduate education: Strategic Reforms for Specialist-Led Allergy teaching in Medical Curricula. A EAACI Tailored Education Committee Task Force
D2.507 - School dust Streptomyces and Mycobacterium exposure and respiratory health in European children: the SINPHONIE study
D2.508 - Climate Change, Allergic Diseases, and Mental Health in Outdoor Workers: A Transdisciplinary Perspective from CliMent COST Action
D2.509 - Do macrophages modulate the response of injured bronchial epithelium after PM2.5 and microplastic exposure?
D2.511 - Beyond PFAS: Atypical oral manifestation of eosinophilic esophagitis in a patient with birch allergy. Case Description
D2.514 - Breathing zone pollen and fungal spore monitoring with an IOM Personal Sampler: A pilot study
D2.515 - Symptom forecasting for birch and grass pollen allergy: the #berlinbreathing project
D2.517 - #berlinbreathing : An app-based citizen science project for pollen allergies
D3.419 - Efficacy, safety, and remission outcomes of omalizumab in elderly patients with severe allergic asthma: a subgroup analysis by age of onset
D3.420 - Real-world epidemiologic characteristics of patients treated with dupilumab for type 2 inflammatory indications: a single-center retrospective cohort study
D3.422 - Dupilumab in children with multimorbid atopic phenotype: therapy efficacy, safety and biomarker changes
D3.424 - Retrospective Analysis of Self-Administration of Biologic Treatments for Severe Asthma and Chronic Urticaria
D3.426 - Predicting response to omalizumab in patients with chronic spontaneous urticaria: The first results of the global multicenter UCARE SCOPUS project
D3.427 - Challenging the paradigm: Use of omalizumab in refractory angioedema in a 2-year-old child
D3.428 - Substratification of Biologic Treatment Using Dupilumab in Eosinophilic COPD
D3.417 - Dupilumab in pediatric patients with severe atopic dermatitis
Download the app
The congress at your fingertips
Available on
Download